Insider Transactions
Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
---|---|---|---|---|---|---|---|
Aug 20, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,000 | -- | 18,000 | |
Jun 26, 2014 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 45,000 | -- | 45,000 | |
Apr 10, 2014 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 50,000 | -- | 51,708 | |
Jan 03, 2014 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 55,000 | -- | 55,000 | |
Jun 18, 2013 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
Jan 28, 2013 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
Jun 04, 2012 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
Feb 15, 2012 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
Jun 16, 2011 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
May 24, 2011 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,250 | $0.64 | 3,958 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.